CA1171952A - Ultrasonic image enhancement - Google Patents

Ultrasonic image enhancement

Info

Publication number
CA1171952A
CA1171952A CA000351273A CA351273A CA1171952A CA 1171952 A CA1171952 A CA 1171952A CA 000351273 A CA000351273 A CA 000351273A CA 351273 A CA351273 A CA 351273A CA 1171952 A CA1171952 A CA 1171952A
Authority
CA
Canada
Prior art keywords
microbubbles
membrane
image
liquid
blood stream
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
CA000351273A
Other languages
French (fr)
Inventor
Ernest G. Tickner
Ned S. Rasor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Schering AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering AG filed Critical Schering AG
Application granted granted Critical
Publication of CA1171952A publication Critical patent/CA1171952A/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B8/00—Diagnosis using ultrasonic, sonic or infrasonic waves
    • A61B8/48—Diagnostic techniques
    • A61B8/481—Diagnostic techniques involving the use of contrast agent, e.g. microbubbles introduced into the bloodstream
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
    • A61K49/222—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
    • A61K49/223—Microbubbles, hollow microspheres, free gas bubbles, gas microspheres
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N29/00—Investigating or analysing materials by the use of ultrasonic, sonic or infrasonic waves; Visualisation of the interior of objects by transmitting ultrasonic or sonic waves through the object
    • G01N29/04—Analysing solids
    • G01N29/06—Visualisation of the interior, e.g. acoustic microscopy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/22—Implements for squeezing-off ulcers or the like on the inside of inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; Calculus removers; Calculus smashing apparatus; Apparatus for removing obstructions in blood vessels, not otherwise provided for
    • A61B2017/22082—Implements for squeezing-off ulcers or the like on the inside of inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; Calculus removers; Calculus smashing apparatus; Apparatus for removing obstructions in blood vessels, not otherwise provided for after introduction of a substance
    • A61B2017/22089—Gas-bubbles
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2291/00—Indexing codes associated with group G01N29/00
    • G01N2291/02—Indexing codes associated with the analysed material
    • G01N2291/028—Material parameters
    • G01N2291/02872—Pressure

Abstract

Ultrasonic Image Enhancement Abstract Ultrasonic images of flowing streams can provide important information regarding the streams. Herein, a plurality of microbubbles are provided in such streams to enhance such images, aid in tumor detection and treatment, provide mapping of vascularity of tissue masses and measure instantaneous blood flow rate. The preferred microbubbles have a coalescence resistant surface membrane encapsulating a gas of a selected composition, the membrane including non-toxic and non-antigenic organic molecules. Preferably, the microbubbles have diameters in the 0.5 micron to 300 microns range.

Description

L95~
Description . _ _ Ultrasonic Image Enhancement Technical Field __ _ This invention relates to an ultrasonic image enhancement method, to diagnostic techniques and to treatment methods which are closely related thereto.

Background Art Contrast agents are often employed medically to accentuate subtle differences between two structures in X-ray radiographic images. In X-ray diagnosis, for example, a radioopaque dye is rountinely injected into an arterial bed to delineate the existing vasculature which otherwise could not be lS detected. Present ultrasonic diagnosis generally faces similar problems. The ultrasonographer has comparable difficulty in detecting certain structures, for example septal defects in small children, but no effective ultrasonic contrast agent has been available. An acceptable ultrasonic contrast agent which can be delivered into the blood stream therefore is greatly needed. A selective agent, i.e., one which can selectively emphasize particular parts of the vasculature (such as that of a tumor), would be especially valuable.
Measurement of cardiac output and other quantitative blood flow measurements are needed to monitor the health of many patients. Existing non-invasive measurement techni~ues are indirect and only approximate. Existing reliable and accurate measurement techniques involve catheterization, a 11~71~5~

difficult and hazardous procedure. Further, the prior art does not yield a measurement of instantaneous blood flow, but only an average value thereof. An accurate non-invasive method for measurement of cardiac output and blood flow in general is greatly needed.
Feigenbaum, et al, Circulation, Volume XLI, Apr:il 1970, report "Identification of Ultrasound Echoes From the Left Ventricle of the Heart Through the Use of Injections of Indocyanine Green" noted that injections of the indocyanine greenproduced a cloud of echoes that filled the left ventricle cavity. They speculated that this phenomenon might be due to the formation of tiny bubbles of air suspended in the dye. Gramiak, et al, Radiology 100:415, 1971 report similar effects.
Although some echoing has been noted and presumed to be caused by microbubbles in the blood stream, the hypothesis that the microbubbles cause the echoing has never been conclusively proven.
Further, .he prior results in this area have been on a hit-or-miss basis, in that the bubbles introduced into the blood stream, if indeed they were bubbles~ have been of generally uncontrollable and unstable size and concentration.
Still further, when the bubbles are simply air bubbles, they have a serious and deleterious tendency to stick to the vessel and cardiac walls and to coalesce and form larger bubbles. Hence, it has not been possible to introduce bubbles that are of relatively uniform size into blood vessels, which bubbles resist coalescence, flow freely with the blood and remain of a relatively uniform size as they dissolve. Thus, diagnostic techniques which might ~7195;~
depend upon havlng freely flowing microbubbles of a controlled size in the blood stream, and in a controlled amount, have not been developed and do not form a part of the ultrasonic dianostic art.
The production of freely flowing microbubbles of a controlled size and their injection into the blood stream for different diagnostic techniques is known. The present inventors, in a report entitled "Non-Invasive Assessment of Pulmonary Hypertension Using The Bubble Ultrasonic Resonance Pressure (BURP) Method" (Report No. HR-62917-lA), April, 1977 sponsored by the Division of Lung Diseases, National Heart, Lung and Blood Institute, report on the production and the attempt to use such bubbles for non-invasively measuring pulmonary artery blood pressure by sensing bubble ultrasonic resonance. Basically, microbubbles are injected into a peripheral vein and their ultrasonic resonance re-emission frequency is measured as they pass through the pulmonary artery. The re-emission resonance frequency (about 100 kHz or less) is determined by applying an ultrasonic probe to the chest of the subject. The bubbles are excited by transmission of continuous ultrasonic radiation (of about lOOkHz) into the body. The microbubbles are not, however, utilized by the prior art for enhancing ultrasonic images. That is, they are not used at mega-Hertz frequencies, e.g., 1 to 10 mega-Hertz, and are not used yia applying short ultrasonic pulses and detecting timed echoes therefrom as with ultrasonic echograms, or via applying continuous waves and examining the changes in transmission characteristics as with existing ultrasonic holographic units.

5~

It would be desirable to provide a method of control-lably and uniformly enhancing ultrasonic lmages of the blood stream of a living subject. Such a method could be utilized, for example, for detecting tumors and other abnormalities, for measuring instantaneous cardiac out-put and flow velocities in other vessels, for delivering gaseous therapeutic agents selectively to tumors or other tissues, and the like.
Disclosure of Invention The present invention is directed toward overcoming one or more of the shortcomings of the prior art as set forth above.
According to one aspect of the invention there is provided a method of enhancing ultrasonic echographic imaging in a liquid enclosed in a vessel by increasing image contrast, comprising: providing a plurality of microbubbles in said liquid, each of said microbubbles having a coalescence resistant surface membrane en-capsulating a chemically inert, non-medical and non-therapeutic gas, said membrane including a multiplicity of non-toxic and non-antigenic organic molecules, said microbubbles having a diameter of no more than about 300 microns and no less than about 0.5 micron; and obtaining an enhanced ultrasonic echographic image of said liquid opposite a position therein containing said microbubbles by increasing the relative contrast between said liquid and said vessel.
According to another aspect of the invention there is provided a method of detecting tumors in a living subject, comprising: providing a substance in a blood stream of said test subject, said substance providing a plurality of microbubbles of a chemically inert, non-medical and non-therapeutic gas in said blood stream, substantially all of said m~crobubbles being of generally a uniform size; obtaining an enhanced ultrasonic echographic image of said bubbles at a possible tumor; and examining said `1~

3 ~7~5~2 image for evidence of neovascularization indicative of said possible tumor.
According to another aspect of the invention there is provided a method of detecting tumors in a living subject, comprising: providing a substance, comprising a plurality of microbubbles each having a surface membrane encapsu- -lating a chemically inert, non-medical and non-therapeutic gas, said membrane including a multiplicity of non-toxic and non-antigenic organic molecules, in a blood stream of said test subject, said substance providing a plurality of microbubbles in said blood stream; obtaining an enhanced ultrasonic echographic image of said bubbles; and ex-amining said image for evidence of neovascularization indicative of a possible tumor.
According to yet another aspect of the invention there is provided a method of mapping the vascularity of a tissue mass, comprising: injecting a plurality of microbubbles, substantially all of which fall in a selected narrow size range, into a blood stream of a test subject, each of said microbubbles having a coalescing resi~tant surface membrane encapsulating a chemically inert, non-medical and non-therapeutic gas, said membrane including a multiplicity of non-tox~c and non-antigenic organic molecules, said molecules having a diameter of between about 0.5 micron and 300 microns: obtaining an enhanced ultrasonic echographic image of the tlssue mass soon after the microbubbles have flowed thereto and lodged at a first bifurcation of a first vascular s~ze corresponding to that of the injected microbubble size range; and obtaining an additional enhanced ultrasonic echographic image o~' the tissue mass a~'ter a selected period of time during which the microbubbles have gen-erally uniformly shrunk, due to dissolution thereof, to a known reduced size, have flowed past said first bifurcation, and have lodged at a second bifurcation of a second vascular size corresponding to that of the '',1`~``

.. . .

5~

reduced size microbubble size range.
According to yet another aspect of the invention there is provided a method of detecting tumorous tissue in a living subject, comprising: providing a substance in an afferent vasculature of said test subject upstream of a possible tumor, said substance providing a plurality of microbubbles of a chemically inert, non-medical and non-therapeutic gas in said blood stream substantially all of a diameter too large to pass through normal capillaries but small enough to pass through tumorous capillaries;
and obtaining an enhanced ultrasonic echographic image of a corresponding efferent vasculature downstream of said possible tumor and noting if such microbubbles are present.
According to yet another aspect of the inventon there is provided a method of enhancing ultrasonic echographic imaging in a liquid enclosed in a vessel by increasing image contrast, comprising: providing a plurality of microbubbles in said liquid, each of said microbubbles having a coalescence resistant surface membrane en-capsulating a chemically inert, non-medical and non-therapeutic gas, said membrane including a multiplicity of non-toxic and non-antigenic organic molecules, said microbubbles having a diameter of no more than about 300 microns and no less than about 0.5 micron; and obtaining an enhanced ultrasonic echographic image of said liquid opposite a position therein containing said microbubbles by increasing the relative contrast between said liquid and said vessel; provided that said vessel does not form a part of a living body.
Other aspects of this invention are claimed in our copending divisional application.
Best Mode For Carryinq Out The Invention In accordance with the present invention ultrasonic images of a blood stream of a subject are enhanced.
Either via catheterization injection or through hypo-dermic injection, a plurality of microbubbles of a very , .~

- 6a -particular nature are inserted into the blood stream of the test s~bject. The microbubbles must each have a surface membrane which encapsulates a gas of a selected composition.
The structure of the membrane is of extreme impor-tance. It should be selected to reduce coalescence and must include a multiplicity of non-toxic and non-antigenic molecules. Gelatin is particularly preferred as the membrane material. The organic molecules which form a gelatin membrane are 5~
believed to have both a hydrophilic portion and a hydrophobic portion. When the membrane-covered microbubbles are in the blood stream, the hydrophilic portions are believed to be aligned radially outwardly or away from the centers of the respective microbubbles. As a result, the microbubbles tend to repel one another thus significantly reducing the tendency of the microbubbles to coalesce with one another and form larger microbubbles.
Membranes other than gelatin and having resistance to coalescing, as well as non-toxic and non-antigenic properties, are also suitable whether the resistance to coalescing is due to the presence of such hydrophilic and hydrophobic portions, to particularly strong membranes, or whatever. This resistance to coalescing is important in ensuring that the si~es of the microbubbles in the blood stream are substantially the same for microbubbles which are originally of the same size and have been 20 in the blood stream an equal length of time. With --time, of course, the gas or gases contained within the membranes will dissolve into the blood stream and the microbubbles will be gradually reduced in size until they disappear.
It is essential that the organic molecules which form the membrane be non-toxic and non-antigenic, since it is clear that either a toxic or antigenic reaction within the blood stream is highly undesirable.
With respect to the gas within the membrane, for straightforward ultrasonic image enhancement, a chemically inert and somewhat slowly dissolving gas such as nitrogen or one of the slower dissolving noble gases is very suitable. However, in certain instances it may be desirable to utilize a gas which is far from inert. For example, it may be desirable to utilize a gas within the bubble which is toxic to tissue, if the bubble is designed to be absorbed by tumorous tissue but to not be absorbed by the normal tissue of the blood stream.
In other instances, it may be desirable to employ a gas which dissolves in blood quickly, such as carbon dioxide.
Another important result of utilizing microbubbles having the particular membrane described above is that they will have a reduced tendency to stick to the walls of the blood vessel, particularly the walls of normal blood vessels. With tumorous tissue, the walls of the blood vessels are considerably rougher and otherwise abnormal, thus providing a more ready accepting surface for holding such microbubbles, even with their reduced tendency to stick to normal blood vessel walls.
The size of such microbubbles is also important. Generally they will be, at most, about 300 microns, and at least about 0.5 micron, in diameter. More preferably, the microbubbles will have a diameter below about 150 microns and above about 1.0 micron. In some instances, all of the micro-bubbles injected will be of about the same size so that they congregate in a particular area of the body or in a particular type or size of blood vessel.
~icrobubbles between 5 and 10 microns areparticularly useful in that they can pass through normal capillaries.
Such microbubbles as have just been described are produced by gradually flowing a gas through a small orifice, for example through a capillary tube, and into a liquid. A force is Z
_ g _ generally exerted upon the microbubble being formed at the orifice, with the force being sufficient to remove the microbubble prior to its attaining the full size it would attain in the absence of such force. For example, the orifice may lie generally in a vertical plane (the capillary may be horizontal) and the force may simply comprise the buoyancy of the microbubble in the liquid and the surface tension attachment to the orifice. Al-ternately, and preferably, the orifice may lie in any orientation with flow past the orlfice, and the force consists of fluid drag on the bubble and the surface tension force. In both situations the microbubbles may flow into a storage container such as a hypodermic syringe. The aforementioned report "Non-Invasive Assessment of Pulmonary Hypertension Using The Bubble Ultrasonic Resonance Pressure (B~RP) Method" describes production of such microbubbles in more detail.
Other methods of producing the described micro-bubbles have been successfully employed. For example, microbubbles have been created by supersaturation of a liquid; air or liquid jet impingement upon a free liquid surface; and addition of NaHCO3 particles to a liquid.
These latter methods permit production of large quantities of microbubbles but of a much broader spectrum of sizes than the highly uniform diameter of microbubbles produced by a submerged orifice.
It is preferred that the microbubbles be formed and dispersed in a medium having a chemical composi-tion substantially identical to that of the membrane.
It is further preferred that the medium be gellable.
As previously mentioned, a particularly preferred membrane material is gelatin itself, because ~J

, ., 1~7195~
it is well known to be non-toxic, non-antigenic and non-allergenic. Utilizing a gellable medium allows the microbubble dispersion to be stored for extended periods of time by simply lowering the temperature of 1:he medium sufficiently so that gelling occurs.
In practice, the gelled microbubble dispersion is stored in hypodermic syringes. When needed, the gelatin is melted by warming the syringes, and the dispersion is injected into a blood vessel. The bulk of the gelatin dissolves in the blood, leaving the required gelatin stabilizing membrane around each microbubble.
~ s the microbubbles flow through the blood stream, ultrasonic images are obtained of the blood stream opposite a location therein through which the microbubbles are flowing. Most modern clinical ultrasonic units employ pulsed ultrasound to obtain images within the body. A short burst of ultrasound is emitted from the exciter/receiver transducer into the test media. Slight changes in acoustical impedance cause some reflection of the incident pulse train. The intensity of the reflection recieved by the transducer is a function of the difference between the acoustical impedance of the two media forming the interface. The time to acquire the return signal depends upon the distance travelled.
Signal and video processing leads to an echogram of the test media, and the brightness of an interface depends upon the strength of the reflection. Use of the ultrasonic echogram technique along with a microbubble contrast medium is identical to that normally utilized. That is, no variations in the ultrasonic imaging device itself are necessary.
It should be noted that the particular 117i~
size of the microbubbles may be optimized in relation to the frequency of the ultrasound being utilized to obtain the image. That is, for a highly reflecting dispersion, the size of the microbubbles can be chosen so that they resonate at the particular ultrasonic frequency utilized, although at the most used imaging frequencies, 2 to 10 mHz, this may require microbubbles having very small (1 to 5 micron) diameters. The reflection power of the bubbles at resonance can be more than 100 times that at non-resonance frequencies.
Instantaneous cardiac output can be measured utilizing microbubbles injected into the blood stream. The blood flow velocity distribution in a blood vessel or heart chamber can be quantitatively determined by the use of injected microbubbles, provided that the bubbles which reach the observed location are of suitable number and size for discrete and aecurate measurement of their position in the ultrasonie image. The velocity distribution is obtainable by either one of two methods. The first method is to observe the loeal displaeement of the bubbles throughout the vessel or ehamber over a short inerement of time. This is conveniently aeeomplished in the usual ultrasonic image by measuring the bubble "streak length", i.e., the ehange in position of each bubble between suecessive ultrasonie scans. The second method is to detect the Doppler shift frequency from the backseattered signal from each bubble. A three-dimensional veloeity field ean be determined stereoscopically using images from different aspects (angles). Such instantaneous distributions ean reveal the presence and quantitative severity of flow ~7i~5'~
abnormalities such as septal defects and valvular disfunctions in the heart, and obstructions or aneurysms in the coronary, aorta, carotoid and other vital blood vessels. Furthermore, by integrating the 5 velocity profile across the diameter of a great vessel of the heart such as the pulmonary artery or the ascending aorta, a direct measurement of instantaneous cardiac output can be obtained non-invasively. This important measurement previously could be obtained only by catheterization, a difficult and hazardous procedure, or by inaccurate and ambiguous indirect methods, and as averages over the cardiac cycle rather than instantaneous values.
Tumors can be detected in a living test lS subject via ultrasonic images by observing the abnormal concentration of microbubbles in an area where a tumor is suspected. Basically, the vasculature of a tumor grows at a rapid rate and becomes erratic and larger than that of normal tissue.
Because the neovascularized vessels are larger than normal vessels, increased blood flow exists and a much higher concentration of microbubbles will be present. In particular, if microbubbles of a particularly appropriate size are chosen, it is possible to selectively collect such microbubbles within the tumor neovasculature and to thus delineate the extent of the neovascularity with a quantitative image. Alternately, by using microbubbles of a uniform size larger than the normal capillary diameter, i.e., 7 to 10 microns, but well within the range of abnormal tumor capillary diameter, i.e., 20 to 100 microns, the local presence of the tumor is unambiguously identified by microbubbles which pass through the afferent vasculature and appear in the ~7~35Z
efferent (venous) vasculature.
Example The following example illustrates the use of microbubbles as ultrasonic contrast agents.
Nitrogen microbubbles (38, 80 and 140 microns in diameter) dispersed in gelatin, were injected via a catheter into test subjects. Static ~5m~z transducer) and real time (7.5mHz transducer) images were record~d on Polaroid film and on videotape. Rabbits with unilateral thigh V2 carcinomas were used in the ln vivo studies. Base-line ultrasound images of normal muscle and V2 carcinoma were obtained. Five milliliter syringes containing a gelatin dispersion of 80 micron nitrogen microbubbles were warmed and injected through a catheter placed in the V2 ipsilateral iliac artery via the right carotid artery. Static and real time images of normal muscle, blood vessels, and the V2 carcinoma, which was located by palpation, were recorded for at least 2 minutes following each injection. The gelatin-encapsulated nitrogen bubbles were also readily demonstrated in an ln vitro phantom. The 80 and 140 micron bubbles were more echogenic that the 38 micron bubbles, although this may be a result of the instrumentation and geometry OL the test. _ vivo, the 80 micron microbubbles could be identified for several minutes after the initial bolus of bubbles. The central anechoic portions of the V2 carcinoma did not become echogenic following injection of microbubbles but the periphery of the tumor became increasingly echogenic. The gelatin-encapsulated nitrogen microbubbles are thus demonstrated as being an effective ultrasonic contrast agent. The ultrasonic tumor rim enhancement ~7~5Z
about a necotic core was found to be a useful diagnostic observation.
The tumor detection technique just discussed and exemplified can be modified to serve as a tumor treatment technique. That is, the gas encapsulated within the membrane can be changed to one which will deliver radioactive orchemotherapeutic agents to the tumor neovascularization. It is noted that such is in conformance with the exemplified concentrating of microbubbles in the neovascularized tumor tissue and with the selectively large dissolution rate of the bubbles in the capillary bed.

Industrial Applicability .. ..
The aforementioned and described methods are useful diagnostically for a number of purposes, including but not limited to the detection of cardiovascular abnormalities and tumors in livin~
beings, and the selective local delivery of therapeutic agents. Still further, the method is useful in providing a direct and non-invasive measurement of instantaneous cardiac output and blood flow in general, whereas it was previously not possible to make such an instantaneous measurement, but rather only to measure average cardiac output or blood flow by invasive or indirect procedures.
Other aspects, objects, and advantages of this invention can be obtained from a study of the drawings, disclosure and the appended claims.

.

Claims (19)

Claims:
1. A method of enhancing ultrasonic echographic imaging in a liquid enclosed in a vessel by increasing image contrast, comprising:
providing a plurality of microbubbles in said liquid, each of said microbubbles having a coalescence resistant surface membrane encapsulating a chemically inert, non-medical and non-therapeutic gas, said membrane including a multiplicity of non-toxic and non-antigenic organic molecules, said microbubbles having a diameter of no more than about 300 microns and no less than about 0.5 micron;
and obtaining an enhanced ultrasonic echographic image of said liquid opposite a position therein containing said microbubbles by increasing the relative contrast between said liquid and said vessel.
2. A method as in claim 1, wherein said liquid is a blood stream of a test subject.
3. A method as in claim 2, wherein said microbubbles having a diameter in the range 5-10 microns are provided.
4. A method as in claim 3, wherein said molecules each have a hydrophilic portion and a hydrophobic portion and said hydrophilic portions of said molecules are aligned radially away from a center of a respective microbubble.
5. A method as in claim 3, wherein said membrane is of a gellable composition.
6. A method as in claim 5, wherein said gellable composi-tion is gelatin.
7. A method of detecting tumors in a living subject, comprising:
providing a substance in a blood stream of said test subject, said substance providing a plurality of micro-bubbles of a chemically inert, non-medical and non-therapeutic gas in said blood stream, substantially all of said microbubbles being of generally a uniform size;
obtaining an enhanced ultrasonic echographic image of said bubbles at a possible tumor; and examining said image for evidence of neovascularization indicative of said possible tumor.
8. A method of detecting tumors in a living subject, comprising:
providing a substance, comprising a plurality of micro-bubbles each having a surface membrane encapsulating a chemically inert, non-medical and non-therapeutic gas, said membrane including a multiplicity of non-toxic and non-antigenic organic molecules, in a blood stream of said test subject, said substance providing a plurality of microbubbles in said blood stream;
obtaining an enhanced ultrasonic echographic image of said bubbles; and examining said image for evidence of neovascularization indicative of a possible tumor.
9. A method as in claim 8, wherein said molecules each have a hydrophilic portion and a hydrophobic portion, said hydrophilic portions of said molecules being aligned radially away from a center of each respective bubble, said microbubbles are of generally a uniform size and of a diameter of no more than about 300 microns and no less than about 0.5 micron.
10. A method as in claim 8, wherein said membrane is of a gellable composition.
11. A method as in claim 8, wherein said membrane comprises gelatin.
12. A method of mapping the vascularity of a tissue mass, comprising:
injecting a plurality of microbubbles, substantially all of which fall in a selected narrow size range, into a blood stream of a test subject, each of said microbubbles having a coalescing resistant surface membrane encapsulat-ing a chemically inert, non-medical and non-therapeutic gas, said membrane including a multiplicity of non-toxic and non-antigenic organic molecules, said molecules having a diameter of between about 0.5 micron and 300 microns;
obtaining an enhanced ultrasonic echographic image of the tissue mass soon after the microbubbles have flowed thereto and lodged at a first bifurcation of a first vascular size corresponding to that of the injected microbubble size range and obtaining an additional enhanced ultrasonic echo-graphic image of the tissue mass after a selected period of time during which the microbubbles have generally uniformly shrunk, due to dissolution thereof, to a known reduced size, have flowed past said first bifurcation, and have lodged at a second bifurcation of a second vascular size corresponding to that of the reduced size microbubble size range.
13. A method as in claim 12, wherein said organic mole-cules each have a hydrophilic portion and a hydrophobic portion, said hydrophilic portions of said molecules being aligned radially away from a center of each respective microbubble.
14. A method as in claim 12, wherein said membrane is of a gellable composition.
15. A method as in claim 14, wherein said gellable composi-tion is gelatin.
16. A method of detecting tumorous tissue in a living subject, comprising:
providing a substance in an afferent vasculature of said test subject upstream of a possible tumor, said substance providing a plurality of microbubbles of a chemically inert, non-medical and non-therapeutic gas in said blood stream substantially all of a diameter too large to pass through normal capillaries but small enough to pass through tumorous capillaries; and obtaining an enhanced ultrasonic echographic image of a corresponding efferent vasculature downstream of said possible tumor and noting if such microbubbles are present.
17. A method of enhancing ultrasonic echographic imaging in a liquid enclosed in a vessel by increasing image contrast, comprising:
providing a plurality of microbubbles in said liquid, each of said microbubbles having a coalescence resistant surface membrane encapsulating a chemically inert, non-medical and non-therapeutic gas, said membrane including a multiplicity of non-toxic and non-antigenic organic molecules, said microbubbles having a diameter of no more than about 300 microns and no less than about 0.5 micron;
and obtaining an enhanced ultrasonic echographic image of said liquid opposite a position therein containing said microbubbles by increasing the relative contrast between said liquid and said vessel;
provided that said vessel does not form a part of a living body.
18. A method according to claim 1, claim 7 or claim 8 wherein the gas is selected from the group consisting of nitrogen and the noble gases.
19. A method according to claim 12, claim 16 or claim 17 wherein the gas is selected from the group consisting of nitrogen and the noble gases.
CA000351273A 1979-05-04 1980-05-05 Ultrasonic image enhancement Expired CA1171952A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/036,098 US4276885A (en) 1979-05-04 1979-05-04 Ultrasonic image enhancement
US36,098 1979-05-04

Publications (1)

Publication Number Publication Date
CA1171952A true CA1171952A (en) 1984-07-31

Family

ID=21886612

Family Applications (1)

Application Number Title Priority Date Filing Date
CA000351273A Expired CA1171952A (en) 1979-05-04 1980-05-05 Ultrasonic image enhancement

Country Status (4)

Country Link
US (1) US4276885A (en)
EP (1) EP0028253A1 (en)
CA (1) CA1171952A (en)
WO (1) WO1980002365A1 (en)

Families Citing this family (260)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3037641A1 (en) * 1980-10-04 1982-05-13 Gesellschaft für Strahlen- und Umweltforschung mbH, 8042 Neuherberg ULTRASONIC TRANSMITTER
JPS58500392A (en) * 1980-11-17 1983-03-17 シエリング、アクテイエンゲゼルシヤフト Microbubble precursors and their production methods and applications
US4442843A (en) * 1980-11-17 1984-04-17 Schering, Ag Microbubble precursors and methods for their production and use
AU545866B2 (en) * 1980-11-17 1985-08-01 Schering Aktiengesellschaft Microbubble precursors and methods for their production and use
DE3141641A1 (en) * 1981-10-16 1983-04-28 Schering Ag, 1000 Berlin Und 4619 Bergkamen ULTRASONIC CONTRAST AGENTS AND THEIR PRODUCTION
US4805628A (en) * 1982-12-06 1989-02-21 Indianapolis Center For Advanced Research, Inc. Ultrasound contrast media for medically implantable and insertable devices
US4572203A (en) * 1983-01-27 1986-02-25 Feinstein Steven B Contact agents for ultrasonic imaging
US4718433A (en) * 1983-01-27 1988-01-12 Feinstein Steven B Contrast agents for ultrasonic imaging
DE3834705A1 (en) 1988-10-07 1990-04-12 Schering Ag ULTRASONIC CONTRASTING AGENTS FROM GAS BUBBLES AND MICROPARTICLES CONTAINING FATTY ACID
DE3324754A1 (en) * 1983-07-06 1985-01-17 Schering AG, 1000 Berlin und 4709 Bergkamen ULTRASONIC CONTRASTING AGENTS AND THEIR PRODUCTION
SE463651B (en) * 1983-12-21 1991-01-07 Nycomed As DIAGNOSTIC AND CONTRACTOR
US5618514A (en) * 1983-12-21 1997-04-08 Nycomed Imaging As Diagnostic and contrast agent
US6203777B1 (en) * 1983-12-21 2001-03-20 Nycomed Imaging As Method of contrast enhanced magnetic resonance imaging using carbohydrate particles
DE3529195A1 (en) * 1985-08-14 1987-02-26 Max Planck Gesellschaft CONTRAST AGENTS FOR ULTRASONIC EXAMINATIONS AND METHOD FOR THE PRODUCTION THEREOF
US4888694A (en) * 1987-10-28 1989-12-19 Quantum Medical Systems, Inc. Ultrasound imaging system for relatively low-velocity blood flow at relatively high frame rates
US5040537A (en) * 1987-11-24 1991-08-20 Hitachi, Ltd. Method and apparatus for the measurement and medical treatment using an ultrasonic wave
DE3741201A1 (en) * 1987-12-02 1989-06-15 Schering Ag ULTRASONIC PROCESS AND METHOD FOR IMPLEMENTING IT
US4844882A (en) * 1987-12-29 1989-07-04 Molecular Biosystems, Inc. Concentrated stabilized microbubble-type ultrasonic imaging agent
US5425366A (en) * 1988-02-05 1995-06-20 Schering Aktiengesellschaft Ultrasonic contrast agents for color Doppler imaging
IE66912B1 (en) 1988-02-05 1996-02-07 Schering Ag Ultrasonic contrast agents process for their preparation and their use as diagnostic and therapeutic agents
DE3803971C2 (en) * 1988-02-05 1997-09-18 Schering Ag Ultrasound contrast media
US5730954A (en) * 1988-08-23 1998-03-24 Schering Aktiengesellschaft Preparation comprising cavitate- or clathrate-forming host/guest complexes as contrast agent
DE3828905A1 (en) * 1988-08-23 1990-03-15 Schering Ag MEDIALLY COMPOSED OF CAVITATE OR CLATHRATE MAKING HOST / GUEST COMPLEX AS A CONTRAST
DE3829999A1 (en) 1988-09-01 1990-03-15 Schering Ag ULTRASONIC METHOD AND CIRCUITS THEREOF
US4957656A (en) * 1988-09-14 1990-09-18 Molecular Biosystems, Inc. Continuous sonication method for preparing protein encapsulated microbubbles
FR2643252B1 (en) * 1989-02-21 1991-06-07 Technomed Int Sa APPARATUS FOR THE SELECTIVE DESTRUCTION OF CELLS INCLUDING SOFT TISSUES AND BONES WITHIN THE BODY OF A LIVING BODY BY IMPLOSION OF GAS BUBBLES
US5656211A (en) * 1989-12-22 1997-08-12 Imarx Pharmaceutical Corp. Apparatus and method for making gas-filled vesicles of optimal size
US5705187A (en) * 1989-12-22 1998-01-06 Imarx Pharmaceutical Corp. Compositions of lipids and stabilizing materials
US5922304A (en) * 1989-12-22 1999-07-13 Imarx Pharmaceutical Corp. Gaseous precursor filled microspheres as magnetic resonance imaging contrast agents
US6146657A (en) * 1989-12-22 2000-11-14 Imarx Pharmaceutical Corp. Gas-filled lipid spheres for use in diagnostic and therapeutic applications
US5334381A (en) * 1989-12-22 1994-08-02 Unger Evan C Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same
US6088613A (en) 1989-12-22 2000-07-11 Imarx Pharmaceutical Corp. Method of magnetic resonance focused surgical and therapeutic ultrasound
US5352435A (en) * 1989-12-22 1994-10-04 Unger Evan C Ionophore containing liposomes for ultrasound imaging
US5305757A (en) * 1989-12-22 1994-04-26 Unger Evan C Gas filled liposomes and their use as ultrasonic contrast agents
US5469854A (en) * 1989-12-22 1995-11-28 Imarx Pharmaceutical Corp. Methods of preparing gas-filled liposomes
US5776429A (en) * 1989-12-22 1998-07-07 Imarx Pharmaceutical Corp. Method of preparing gas-filled microspheres using a lyophilized lipids
US5230882A (en) * 1989-12-22 1993-07-27 Unger Evan C Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same
US6551576B1 (en) 1989-12-22 2003-04-22 Bristol-Myers Squibb Medical Imaging, Inc. Container with multi-phase composition for use in diagnostic and therapeutic applications
US5149319A (en) * 1990-09-11 1992-09-22 Unger Evan C Methods for providing localized therapeutic heat to biological tissues and fluids
US5088499A (en) * 1989-12-22 1992-02-18 Unger Evan C Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same
US5580575A (en) * 1989-12-22 1996-12-03 Imarx Pharmaceutical Corp. Therapeutic drug delivery systems
US20020150539A1 (en) 1989-12-22 2002-10-17 Unger Evan C. Ultrasound imaging and treatment
US5733572A (en) * 1989-12-22 1998-03-31 Imarx Pharmaceutical Corp. Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles
US5773024A (en) * 1989-12-22 1998-06-30 Imarx Pharmaceutical Corp. Container with multi-phase composition for use in diagnostic and therapeutic applications
US5123414A (en) * 1989-12-22 1992-06-23 Unger Evan C Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same
US6001335A (en) * 1989-12-22 1999-12-14 Imarx Pharmaceutical Corp. Contrasting agents for ultrasonic imaging and methods for preparing the same
US5542935A (en) * 1989-12-22 1996-08-06 Imarx Pharmaceutical Corp. Therapeutic delivery systems related applications
US5585112A (en) * 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
DE4004430A1 (en) * 1990-02-09 1991-08-14 Schering Ag CONSTRUCTED POLYALDEHYDE CONSTITUENTS
US20010024638A1 (en) * 1992-11-02 2001-09-27 Michel Schneider Stable microbubble suspensions as enhancement agents for ultrasound echography and dry formulations thereof
US5578292A (en) * 1991-11-20 1996-11-26 Bracco International B.V. Long-lasting aqueous dispersions or suspensions of pressure-resistant gas-filled microvesicles and methods for the preparation thereof
US6989141B2 (en) * 1990-05-18 2006-01-24 Bracco International B.V. Ultrasound contrast agents and methods of making and using them
US6613306B1 (en) * 1990-04-02 2003-09-02 Bracco International B.V. Ultrasound contrast agents and methods of making and using them
USRE39146E1 (en) 1990-04-02 2006-06-27 Bracco International B.V. Long-lasting aqueous dispersions or suspensions of pressure-resistant gas-filled microvesicles and methods for the preparation thereof
US5445813A (en) * 1992-11-02 1995-08-29 Bracco International B.V. Stable microbubble suspensions as enhancement agents for ultrasound echography
IN172208B (en) * 1990-04-02 1993-05-01 Sint Sa
US7083778B2 (en) * 1991-05-03 2006-08-01 Bracco International B.V. Ultrasound contrast agents and methods of making and using them
US20040208826A1 (en) * 1990-04-02 2004-10-21 Bracco International B.V. Ultrasound contrast agents and methods of making and using them
US5137928A (en) * 1990-04-26 1992-08-11 Hoechst Aktiengesellschaft Ultrasonic contrast agents, processes for their preparation and the use thereof as diagnostic and therapeutic agents
US5190982A (en) * 1990-04-26 1993-03-02 Hoechst Aktiengesellschaft Ultrasonic contrast agents, processes for their preparation and the use thereof as diagnostic and therapeutic agents
GB9009423D0 (en) * 1990-04-26 1990-06-20 Williams Alun R Assessment of vascular perfusion by the display of harmonic echoes from ultrasonically excited gas bubbles
US5205287A (en) * 1990-04-26 1993-04-27 Hoechst Aktiengesellschaft Ultrasonic contrast agents, processes for their preparation and the use thereof as diagnostic and therapeutic agents
US20030194376A1 (en) * 1990-05-18 2003-10-16 Bracco International B.V. Ultrasound contrast agents and methods of making and using them
AU636481B2 (en) * 1990-05-18 1993-04-29 Bracco International B.V. Polymeric gas or air filled microballoons usable as suspensions in liquid carriers for ultrasonic echography
US5215680A (en) * 1990-07-10 1993-06-01 Cavitation-Control Technology, Inc. Method for the production of medical-grade lipid-coated microbubbles, paramagnetic labeling of such microbubbles and therapeutic uses of microbubbles
US5487390A (en) * 1990-10-05 1996-01-30 Massachusetts Institute Of Technology Gas-filled polymeric microbubbles for ultrasound imaging
US5562099A (en) * 1990-10-05 1996-10-08 Massachusetts Institute Of Technology Polymeric microparticles containing agents for imaging
US5179955A (en) * 1991-02-22 1993-01-19 Molecular Biosystems, Inc. Method of abdominal ultrasound imaging
DE69215722T3 (en) * 1991-03-22 2001-03-08 Katsuro Tachibana Amplifiers for ultrasound therapy of diseases and liquid pharmaceutical compositions containing them
GB9106686D0 (en) * 1991-03-28 1991-05-15 Hafslund Nycomed As Improvements in or relating to contrast agents
US5874062A (en) * 1991-04-05 1999-02-23 Imarx Pharmaceutical Corp. Methods of computed tomography using perfluorocarbon gaseous filled microspheres as contrast agents
US5205290A (en) 1991-04-05 1993-04-27 Unger Evan C Low density microspheres and their use as contrast agents for computed tomography
GB9107628D0 (en) * 1991-04-10 1991-05-29 Moonbrook Limited Preparation of diagnostic agents
US5993805A (en) * 1991-04-10 1999-11-30 Quadrant Healthcare (Uk) Limited Spray-dried microparticles and their use as therapeutic vehicles
EP0593627A1 (en) * 1991-07-05 1994-04-27 The University Of Rochester Ultrasmall non-aggregated porous particles entrapping gas-bubbles
US5409688A (en) * 1991-09-17 1995-04-25 Sonus Pharmaceuticals, Inc. Gaseous ultrasound contrast media
MX9205298A (en) 1991-09-17 1993-05-01 Steven Carl Quay GASEOUS ULTRASOUND CONTRASTING MEDIA AND METHOD FOR SELECTING GASES TO BE USED AS ULTRASOUND CONTRASTING MEDIA
US6723303B1 (en) 1991-09-17 2004-04-20 Amersham Health, As Ultrasound contrast agents including protein stabilized microspheres of perfluoropropane, perfluorobutane or perfluoropentane
ES2145011T5 (en) * 1991-09-17 2008-02-01 Ge Healthcare As GAS CONTRAST MEANS FOR ECOGRAPHIES.
DE4135860C2 (en) * 1991-10-31 1993-10-28 Schering Ag Method and device for examining ultrasound contrast media based on microbubbles
US5325860A (en) * 1991-11-08 1994-07-05 Mayo Foundation For Medical Education And Research Ultrasonic and interventional catheter and method
US5255683A (en) * 1991-12-30 1993-10-26 Sound Science Limited Partnership Methods of and systems for examining tissue perfusion using ultrasonic contrast agents
GB9200388D0 (en) * 1992-01-09 1992-02-26 Nycomed As Improvements in or relating to contrast agents
IL104084A (en) 1992-01-24 1996-09-12 Bracco Int Bv Long-lasting aqueous suspensions of pressure-resistant gas-filled microvesicles their preparation and contrast agents consisting of them
GB9204918D0 (en) 1992-03-06 1992-04-22 Nycomed As Chemical compounds
US6383470B1 (en) 1992-09-26 2002-05-07 Thomas Fritzsch Microparticle preparations made of biodegradable copolymers
GB9221329D0 (en) * 1992-10-10 1992-11-25 Delta Biotechnology Ltd Preparation of further diagnostic agents
IL108416A (en) 1993-01-25 1998-10-30 Sonus Pharma Inc Phase shift colloids as ultrasound contrast agents
HUT72323A (en) * 1993-01-25 1996-04-29 Sonus Pharma Inc Phase shift colloids as ultrasound contrast agents
US5558855A (en) * 1993-01-25 1996-09-24 Sonus Pharmaceuticals Phase shift colloids as ultrasound contrast agents
US5333613A (en) * 1993-03-23 1994-08-02 Delineate Microparticles as ultrasonic contrast media
US5716597A (en) * 1993-06-04 1998-02-10 Molecular Biosystems, Inc. Emulsions as contrast agents and method of use
ES2068151B1 (en) 1993-06-23 1995-11-16 Cabrera Garrido Juan INJECTABLE MICROS FOAM FOR SCLEROSIS.
DE69434119T3 (en) * 1993-07-30 2011-05-05 Imcor Pharmaceutical Co., San Diego STABILIZED MICROGAS BLOWER COMPOSITIONS FOR ECHOGRAPHY
US5798091A (en) 1993-07-30 1998-08-25 Alliance Pharmaceutical Corp. Stabilized gas emulsion containing phospholipid for ultrasound contrast enhancement
DE4330958A1 (en) * 1993-09-09 1995-03-16 Schering Ag Novel microparticles containing active compound, media containing these, their use for the ultrasonically controlled release of active compounds and process for the production thereof
US7083572B2 (en) 1993-11-30 2006-08-01 Bristol-Myers Squibb Medical Imaging, Inc. Therapeutic delivery systems
AU679295B2 (en) * 1993-12-15 1997-06-26 Bracco Suisse S.A. Gas mixtures useful as ultrasound contrast media
AU2432795A (en) * 1994-05-03 1995-11-29 Molecular Biosystems, Inc. Composition for ultrasonically quantitating myocardial perfusion
US5736121A (en) * 1994-05-23 1998-04-07 Imarx Pharmaceutical Corp. Stabilized homogenous suspensions as computed tomography contrast agents
US5462059A (en) * 1994-05-25 1995-10-31 The Regents Of The University Of California Method for assessing and displaying vascular architecture using ultrasound
US5390677A (en) * 1994-05-31 1995-02-21 The Regents Of The University Of California Method for assessing and displaying the true three dimensional magnitude of blood velocity
US5540909A (en) * 1994-09-28 1996-07-30 Alliance Pharmaceutical Corp. Harmonic ultrasound imaging with microbubbles
GB9423419D0 (en) 1994-11-19 1995-01-11 Andaris Ltd Preparation of hollow microcapsules
US6743779B1 (en) 1994-11-29 2004-06-01 Imarx Pharmaceutical Corp. Methods for delivering compounds into a cell
IL116328A (en) * 1994-12-16 1999-09-22 Bracco Research Sa Frozen suspension of gas microbubbles in frozen aqueous carrier for use as contrast agent in ultrasonic imaging
US5830430A (en) * 1995-02-21 1998-11-03 Imarx Pharmaceutical Corp. Cationic lipids and the use thereof
US5997898A (en) * 1995-06-06 1999-12-07 Imarx Pharmaceutical Corp. Stabilized compositions of fluorinated amphiphiles for methods of therapeutic delivery
US5558092A (en) * 1995-06-06 1996-09-24 Imarx Pharmaceutical Corp. Methods and apparatus for performing diagnostic and therapeutic ultrasound simultaneously
US6521211B1 (en) 1995-06-07 2003-02-18 Bristol-Myers Squibb Medical Imaging, Inc. Methods of imaging and treatment with targeted compositions
US6033645A (en) * 1996-06-19 2000-03-07 Unger; Evan C. Methods for diagnostic imaging by regulating the administration rate of a contrast agent
US6231834B1 (en) 1995-06-07 2001-05-15 Imarx Pharmaceutical Corp. Methods for ultrasound imaging involving the use of a contrast agent and multiple images and processing of same
US6139819A (en) * 1995-06-07 2000-10-31 Imarx Pharmaceutical Corp. Targeted contrast agents for diagnostic and therapeutic use
US5804162A (en) * 1995-06-07 1998-09-08 Alliance Pharmaceutical Corp. Gas emulsions stabilized with fluorinated ethers having low Ostwald coefficients
US5897851A (en) * 1995-06-07 1999-04-27 Sonus Pharmaceuticals, Inc. Nucleation and activation of a liquid-in-liquid emulsion for use in ultrasound imaging
JPH0975348A (en) * 1995-09-12 1997-03-25 Toshiba Corp Ultrasonic diagnostic equipment
US5833613A (en) * 1996-09-27 1998-11-10 Advanced Technology Laboratories, Inc. Ultrasonic diagnostic imaging with contrast agents
US5611344A (en) * 1996-03-05 1997-03-18 Acusphere, Inc. Microencapsulated fluorinated gases for use as imaging agents
PT904113E (en) * 1996-03-05 2004-09-30 Acusphere Inc FLUORATED GASES MICROENCAPSULATED FOR USE AS IMAGE ACQUISITIVE AGENTS
WO1997040679A1 (en) 1996-05-01 1997-11-06 Imarx Pharmaceutical Corp. Methods for delivering compounds into a cell
US6652837B1 (en) 1996-05-24 2003-11-25 Massachusetts Institute Of Technology Preparation of novel particles for inhalation
US5985309A (en) * 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
JPH105216A (en) * 1996-06-19 1998-01-13 Ge Yokogawa Medical Syst Ltd Ultrasonic photographing method and apparatus and contast medium therefor
US5837221A (en) * 1996-07-29 1998-11-17 Acusphere, Inc. Polymer-lipid microencapsulated gases for use as imaging agents
US6414139B1 (en) 1996-09-03 2002-07-02 Imarx Therapeutics, Inc. Silicon amphiphilic compounds and the use thereof
US6017310A (en) * 1996-09-07 2000-01-25 Andaris Limited Use of hollow microcapsules
US5846517A (en) * 1996-09-11 1998-12-08 Imarx Pharmaceutical Corp. Methods for diagnostic imaging using a renal contrast agent and a vasodilator
CA2263568C (en) * 1996-09-11 2008-12-02 Imarx Pharmaceutical Corp. Methods for diagnostic imaging using a contrast agent and a renal vasodilator
US7229413B2 (en) * 1996-11-06 2007-06-12 Angiotech Biocoatings Corp. Echogenic coatings with overcoat
US6106473A (en) * 1996-11-06 2000-08-22 Sts Biopolymers, Inc. Echogenic coatings
US7104956B1 (en) 1996-11-08 2006-09-12 Research Corporation Technologies, Inc. Finite amplitude distortion-based inhomogeneous pulse echo ultrasonic imaging
US6068600A (en) * 1996-12-06 2000-05-30 Quadrant Healthcare (Uk) Limited Use of hollow microcapsules
US6143276A (en) * 1997-03-21 2000-11-07 Imarx Pharmaceutical Corp. Methods for delivering bioactive agents to regions of elevated temperatures
US6120751A (en) 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
US6090800A (en) * 1997-05-06 2000-07-18 Imarx Pharmaceutical Corp. Lipid soluble steroid prodrugs
US6537246B1 (en) 1997-06-18 2003-03-25 Imarx Therapeutics, Inc. Oxygen delivery agents and uses for the same
GB9708246D0 (en) 1997-04-24 1997-06-18 Nycomed Imaging As Improvements in or relating to ultrasound imaging
US7452551B1 (en) 2000-10-30 2008-11-18 Imarx Therapeutics, Inc. Targeted compositions for diagnostic and therapeutic use
US5833615A (en) * 1997-05-09 1998-11-10 Thomas Jefferson University Excitation enhanced ultrasound system
US6416740B1 (en) 1997-05-13 2002-07-09 Bristol-Myers Squibb Medical Imaging, Inc. Acoustically active drug delivery systems
US6045777A (en) * 1997-06-30 2000-04-04 Acusphere, Inc. Method for enhancing the echogenicity and decreasing the attenuation of microencapsulated gases
US6548047B1 (en) 1997-09-15 2003-04-15 Bristol-Myers Squibb Medical Imaging, Inc. Thermal preactivation of gaseous precursor filled compositions
US7637948B2 (en) * 1997-10-10 2009-12-29 Senorx, Inc. Tissue marking implant
US8668737B2 (en) 1997-10-10 2014-03-11 Senorx, Inc. Tissue marking implant
US6123923A (en) * 1997-12-18 2000-09-26 Imarx Pharmaceutical Corp. Optoacoustic contrast agents and methods for their use
US20010003580A1 (en) 1998-01-14 2001-06-14 Poh K. Hui Preparation of a lipid blend and a phospholipid suspension containing the lipid blend
US6758848B2 (en) 1998-03-03 2004-07-06 Senorx, Inc. Apparatus and method for accessing a body site
US6638234B2 (en) 1998-03-03 2003-10-28 Senorx, Inc. Sentinel node location and biopsy
US6875182B2 (en) 1998-03-03 2005-04-05 Senorx, Inc. Electrosurgical specimen-collection system
US6497706B1 (en) 1998-03-03 2002-12-24 Senorx, Inc. Biopsy device and method of use
US6074348A (en) * 1998-03-31 2000-06-13 General Electric Company Method and apparatus for enhanced flow imaging in B-mode ultrasound
US6210332B1 (en) 1998-03-31 2001-04-03 General Electric Company Method and apparatus for flow imaging using coded excitation
US6312384B1 (en) 1998-03-31 2001-11-06 General Electric Company Method and apparatus for flow imaging using golay codes
US6186949B1 (en) 1998-03-31 2001-02-13 General Electric Company Method and apparatus for three-dimensional flow imaging using coded excitation
US6347241B2 (en) * 1999-02-02 2002-02-12 Senorx, Inc. Ultrasonic and x-ray detectable biopsy site marker and apparatus for applying it
US6161034A (en) * 1999-02-02 2000-12-12 Senorx, Inc. Methods and chemical preparations for time-limited marking of biopsy sites
US6540695B1 (en) 1998-04-08 2003-04-01 Senorx, Inc. Biopsy anchor device with cutter
US6245027B1 (en) * 1998-04-10 2001-06-12 Noam Alperin Method of measuring intracranial pressure
US6102858A (en) * 1998-04-23 2000-08-15 General Electric Company Method and apparatus for three-dimensional ultrasound imaging using contrast agents and harmonic echoes
DE69916822T2 (en) * 1998-04-28 2005-04-21 Amersham Health As Oslo IMPROVEMENT OF SEPARATION PROCESSES
GB9813568D0 (en) 1998-06-23 1998-08-19 Nycomed Imaging As Improvements in or relating to cardiac imaging
AUPP431898A0 (en) * 1998-06-24 1998-07-16 Northern Cardiac Sonography Pty Ltd Ultrasonic cardiac output monitor
US6679851B2 (en) 1998-09-01 2004-01-20 Senorx, Inc. Tissue accessing and anchoring device and method
US7983734B2 (en) 2003-05-23 2011-07-19 Senorx, Inc. Fibrous marker and intracorporeal delivery thereof
US20080039819A1 (en) * 2006-08-04 2008-02-14 Senorx, Inc. Marker formed of starch or other suitable polysaccharide
US20090030309A1 (en) * 2007-07-26 2009-01-29 Senorx, Inc. Deployment of polysaccharide markers
US6862470B2 (en) 1999-02-02 2005-03-01 Senorx, Inc. Cavity-filling biopsy site markers
US6725083B1 (en) 1999-02-02 2004-04-20 Senorx, Inc. Tissue site markers for in VIVO imaging
US8361082B2 (en) 1999-02-02 2013-01-29 Senorx, Inc. Marker delivery device with releasable plug
US8498693B2 (en) * 1999-02-02 2013-07-30 Senorx, Inc. Intracorporeal marker and marker delivery device
US9820824B2 (en) 1999-02-02 2017-11-21 Senorx, Inc. Deployment of polysaccharide markers for treating a site within a patent
US7651505B2 (en) 2002-06-17 2010-01-26 Senorx, Inc. Plugged tip delivery for marker placement
GB9912356D0 (en) * 1999-05-26 1999-07-28 Btg Int Ltd Generation of microfoam
US6575991B1 (en) 1999-06-17 2003-06-10 Inrad, Inc. Apparatus for the percutaneous marking of a lesion
EP1289565B1 (en) 2000-06-02 2015-04-22 Bracco Suisse SA Compounds for targeting endothelial cells
CA2659518A1 (en) * 2000-11-20 2002-05-30 Senorx, Inc. Tissue site markers for in vivo imaging
GB0028692D0 (en) * 2000-11-24 2001-01-10 Btg Int Ltd Generation of therapeutic microform
US8512680B2 (en) * 2001-08-08 2013-08-20 Btg International Ltd. Injectables in foam, new pharmaceutical applications
WO2003084173A1 (en) * 2002-03-28 2003-10-09 British Telecommunications Public Limited Company Synchronisation in multi-modal interfaces
US20060036158A1 (en) 2003-11-17 2006-02-16 Inrad, Inc. Self-contained, self-piercing, side-expelling marking apparatus
DK1590006T3 (en) * 2003-02-04 2010-12-20 Bracco Suisse Sa Ultrasound contrast agents and methods for producing them
US20070128117A1 (en) * 2003-02-04 2007-06-07 Bracco International B.V. Ultrasound contrast agents and process for the preparation thereof
US7877133B2 (en) * 2003-05-23 2011-01-25 Senorx, Inc. Marker or filler forming fluid
US20050119562A1 (en) * 2003-05-23 2005-06-02 Senorx, Inc. Fibrous marker formed of synthetic polymer strands
US20050273002A1 (en) * 2004-06-04 2005-12-08 Goosen Ryan L Multi-mode imaging marker
US8048439B2 (en) * 2003-11-17 2011-11-01 Btg International Ltd. Therapeutic foam
ES2339117T5 (en) * 2003-11-17 2019-04-10 Btg Int Ltd Procedures for preparing a foam comprising a sclerosing agent
WO2005063305A1 (en) * 2003-12-22 2005-07-14 Bracco Research Sa Gas-filled microvesicle assembly for contrast imaging
JP2007515471A (en) * 2003-12-22 2007-06-14 ブラッコ・リサーチ・ソシエテ・アノニム Assembly of gas-filled microvesicles with active ingredients for contrast imaging
US9408592B2 (en) 2003-12-23 2016-08-09 Senorx, Inc. Biopsy device with aperture orientation and improved tip
US8708909B2 (en) 2004-01-20 2014-04-29 Fujifilm Visualsonics, Inc. High frequency ultrasound imaging using contrast agents
US7025726B2 (en) 2004-01-22 2006-04-11 The Regents Of The University Of Nebraska Detection of endothelial dysfunction by ultrasonic imaging
US8012457B2 (en) 2004-06-04 2011-09-06 Acusphere, Inc. Ultrasound contrast agent dosage formulation
US9248204B2 (en) 2004-08-18 2016-02-02 Bracco Suisse S.A. Gas-filled microvesicles composition for contrast imaging
WO2006046202A1 (en) * 2004-10-29 2006-05-04 Koninklijke Philips Electronics N.V. Apparatus and methods for the production of ultrasound contrast agents
US8360990B2 (en) 2004-12-16 2013-01-29 Senorx, Inc. Biopsy device with aperture orientation and improved tip
EP1714642A1 (en) * 2005-04-18 2006-10-25 Bracco Research S.A. Pharmaceutical composition comprising gas-filled microcapsules for ultrasound mediated delivery
US10357328B2 (en) 2005-04-20 2019-07-23 Bard Peripheral Vascular, Inc. and Bard Shannon Limited Marking device with retractable cannula
GB0509824D0 (en) * 2005-05-13 2005-06-22 Btg Int Ltd Therapeutic foam
US9095325B2 (en) 2005-05-23 2015-08-04 Senorx, Inc. Tissue cutting member for a biopsy device
US8317725B2 (en) 2005-08-05 2012-11-27 Senorx, Inc. Biopsy device with fluid delivery to tissue specimens
US7572236B2 (en) 2005-08-05 2009-08-11 Senorx, Inc. Biopsy device with fluid delivery to tissue specimens
US9011473B2 (en) 2005-09-07 2015-04-21 Ulthera, Inc. Dissection handpiece and method for reducing the appearance of cellulite
WO2007030415A2 (en) * 2005-09-07 2007-03-15 The Foundry, Inc. Apparatus and method for disrupting subcutaneous structures
US9486274B2 (en) 2005-09-07 2016-11-08 Ulthera, Inc. Dissection handpiece and method for reducing the appearance of cellulite
US10548659B2 (en) 2006-01-17 2020-02-04 Ulthera, Inc. High pressure pre-burst for improved fluid delivery
US9358033B2 (en) 2005-09-07 2016-06-07 Ulthera, Inc. Fluid-jet dissection system and method for reducing the appearance of cellulite
US7967763B2 (en) * 2005-09-07 2011-06-28 Cabochon Aesthetics, Inc. Method for treating subcutaneous tissues
US8518069B2 (en) 2005-09-07 2013-08-27 Cabochon Aesthetics, Inc. Dissection handpiece and method for reducing the appearance of cellulite
US8052658B2 (en) 2005-10-07 2011-11-08 Bard Peripheral Vascular, Inc. Drug-eluting tissue marker
US20080200864A1 (en) * 2005-12-02 2008-08-21 Cabochon Aesthetics, Inc. Devices and methods for selectively lysing cells
US20080197517A1 (en) * 2005-12-02 2008-08-21 Cabochon Aesthetics, Inc. Devices and methods for selectively lysing cells
US20080014627A1 (en) * 2005-12-02 2008-01-17 Cabochon Aesthetics, Inc. Devices and methods for selectively lysing cells
US7885793B2 (en) 2007-05-22 2011-02-08 International Business Machines Corporation Method and system for developing a conceptual model to facilitate generating a business-aligned information technology solution
US20080195036A1 (en) * 2005-12-02 2008-08-14 Cabochon Aesthetics, Inc. Devices and methods for selectively lysing cells
US20080200863A1 (en) * 2005-12-02 2008-08-21 Cabochon Aesthetics, Inc. Devices and methods for selectively lysing cells
US9248317B2 (en) * 2005-12-02 2016-02-02 Ulthera, Inc. Devices and methods for selectively lysing cells
US20080230001A1 (en) * 2006-02-23 2008-09-25 Meadwestvaco Corporation Method for treating a substrate
WO2007127176A2 (en) 2006-04-24 2007-11-08 Ekos Corporation Ultrasound therapy system
US7945307B2 (en) * 2006-08-04 2011-05-17 Senorx, Inc. Marker delivery system with obturator
US20090171198A1 (en) * 2006-08-04 2009-07-02 Jones Michael L Powdered marker
US8064987B2 (en) 2006-10-23 2011-11-22 C. R. Bard, Inc. Breast marker
EP3542748B1 (en) * 2006-12-12 2023-08-16 C. R. Bard, Inc. Multiple imaging mode tissue marker
ES2432572T3 (en) * 2006-12-18 2013-12-04 C.R. Bard, Inc. Biopsy marker with imaging properties generated in situ
EP2117603A2 (en) * 2006-12-19 2009-11-18 Bracco International B.V. Targeting and therapeutic compounds and gas-filled microvesicles comprising said compounds
US8439940B2 (en) 2010-12-22 2013-05-14 Cabochon Aesthetics, Inc. Dissection handpiece with aspiration means for reducing the appearance of cellulite
US8311610B2 (en) * 2008-01-31 2012-11-13 C. R. Bard, Inc. Biopsy tissue marker
US9327061B2 (en) 2008-09-23 2016-05-03 Senorx, Inc. Porous bioabsorbable implant
AU2009301141B2 (en) * 2008-10-07 2015-08-27 Bracco Suisse S.A. Targeting construct comprising anti-polymer antibody and liposomes or microvesicles binding to the same
US8670818B2 (en) 2008-12-30 2014-03-11 C. R. Bard, Inc. Marker delivery device for tissue marker placement
US10258563B2 (en) 2009-04-20 2019-04-16 Drexel University Encapsulation of microbubbles within the aqueous core of microcapsules
US8383671B1 (en) * 2009-06-18 2013-02-26 Abbott Cardiovascular Systems Inc. Method of treating malignant solid tumors
US9358064B2 (en) 2009-08-07 2016-06-07 Ulthera, Inc. Handpiece and methods for performing subcutaneous surgery
US11096708B2 (en) 2009-08-07 2021-08-24 Ulthera, Inc. Devices and methods for performing subcutaneous surgery
US20120136255A1 (en) 2010-06-07 2012-05-31 Shu Feng Fan Tissue malignant tumor detection method and tissue malignant tumor detection apparatus
US9211348B2 (en) 2010-08-09 2015-12-15 Bracco Suisse S.A. Targeted gas-filled microvesicles
US9770411B2 (en) 2010-12-24 2017-09-26 Bracco Suisse S.A. Methods of using gas-filled microvesicles covalently bound to an antigen
DE102011005444A1 (en) * 2011-03-11 2012-09-13 Innora Gmbh Solid, negative X-ray contrast agent for imaging of the gastrointestinal tract
WO2013151682A1 (en) 2012-04-06 2013-10-10 Children's Medical Center Corporation Process for forming microbubbles with high oxygen content and uses thereof
US20150343079A1 (en) 2012-10-25 2015-12-03 Sogang University Research Foundation Ultrasound contrast agent with nanoparticles including drug and method for preparing the same
US20160030151A1 (en) 2013-03-14 2016-02-04 Volcano Corporation Filters with echogenic characteristics
US10292677B2 (en) 2013-03-14 2019-05-21 Volcano Corporation Endoluminal filter having enhanced echogenic properties
US10219887B2 (en) 2013-03-14 2019-03-05 Volcano Corporation Filters with echogenic characteristics
WO2014143808A1 (en) * 2013-03-15 2014-09-18 Children's Medical Center Corporation Hollow particles encapsulating a biological gas and methods of use
JP2016517333A (en) 2013-03-15 2016-06-16 ボルケーノ コーポレイション Distal protection system and method with pressure and ultrasound capabilities
WO2014144364A1 (en) 2013-03-15 2014-09-18 Children's Medical Center Corporation Gas-filled stabilized particles and methods of use
CN103267800B (en) * 2013-05-03 2015-08-05 西安交通大学 The ultrasonic fast imaging of cavitation microvesicle high s/n ratio and dynamic dimension distribution estimation method
USD716450S1 (en) 2013-09-24 2014-10-28 C. R. Bard, Inc. Tissue marker for intracorporeal site identification
USD715942S1 (en) 2013-09-24 2014-10-21 C. R. Bard, Inc. Tissue marker for intracorporeal site identification
USD715442S1 (en) 2013-09-24 2014-10-14 C. R. Bard, Inc. Tissue marker for intracorporeal site identification
USD716451S1 (en) 2013-09-24 2014-10-28 C. R. Bard, Inc. Tissue marker for intracorporeal site identification
KR101595795B1 (en) 2014-03-19 2016-02-22 (주)아이엠지티 Dual-Purpose PAT/Ultrasound Contrast Agent with Nanoparticles Including Drug and Method for Preparing the Same
EP3197368B1 (en) 2014-09-24 2018-11-28 Koninklijke Philips N.V. Endoluminal filter having enhanced echogenic properties
EA201791437A1 (en) 2014-12-31 2017-12-29 Лантеус Медикал Имэджинг, Инк. COMPOSITIONS OF MICROSPHERE WITH GAS DISTRIBUTED IN LIPID AND RELATED METHODS
KR20180104166A (en) 2016-02-09 2018-09-19 브라코 스위스 에스.에이. Recombinant chimeric protein for selectin targeting
JP2019515936A (en) 2016-05-04 2019-06-13 ランセウス メディカル イメージング， インコーポレイテッド Methods and devices for preparing ultrasound contrast agents
US9789210B1 (en) 2016-07-06 2017-10-17 Lantheus Medical Imaging, Inc. Methods for making ultrasound contrast agents
US11364011B2 (en) 2016-08-04 2022-06-21 University Of Virginia Patent Foundation Ultrasound contrast agent decorrelation-based signal separation
WO2018160752A1 (en) 2017-02-28 2018-09-07 Children's Medical Center Corporation Stimuli-responsive particles encapsulating a gas and methods of use

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3522346A (en) * 1968-05-31 1970-07-28 Research Corp Nonthrombogenic microcapsules
US3585149A (en) * 1968-12-23 1971-06-15 Us Plywood Champ Papers Inc Microcapsular opacifier system
US3640271A (en) * 1969-06-30 1972-02-08 Ibm Blood flow pressure measurement technique employing injected bubbled and ultrasonic frequency scanning
US3621715A (en) * 1969-08-06 1971-11-23 Lkb Produkter Ab System for measuring the flow volume of a liquid flow
US3739636A (en) * 1971-01-22 1973-06-19 A Versaci Linear readout flowmeter
SE420565B (en) * 1974-06-06 1981-10-19 Pharmacia Ab AID FOR INTRAVASCULAR ADMINISTRATION FOR USE IN CONNECTION WITH INTRAVASCULAR ADMINISTRATION OF A SOLUTION OR SUSPENSION OF A DIAGNOSTIC AGENT
US4182173A (en) * 1978-08-23 1980-01-08 General Electric Company Duplex ultrasonic imaging system with repetitive excitation of common transducer in doppler modality

Also Published As

Publication number Publication date
WO1980002365A1 (en) 1980-11-13
EP0028253A1 (en) 1981-05-13
US4276885A (en) 1981-07-07

Similar Documents

Publication Publication Date Title
CA1171952A (en) Ultrasonic image enhancement
US4316391A (en) Flow rate measurement
Meltzer et al. The source of ultrasound contrast effect
Meltzer et al. Why do the lungs clear ultrasonic contrast?
Ophir et al. Contrast agents in diagnostic ultrasound
US4572203A (en) Contact agents for ultrasonic imaging
US5740807A (en) Suspended ultra-sound induced microbubble cavitation imaging
US4718433A (en) Contrast agents for ultrasonic imaging
Ries et al. A transpulmonary contrast medium enhances the transcranial Doppler signal in humans.
de Jong Improvements in ultrasound contrast agents
Kremer et al. Ultrasonic in vivo and in vitro studies on the nature of the ureteral jet phenomenon.
Nanda et al. Echo-enhancing agents: safety
Schlief et al. Saccharide based contrast agents
Wu et al. Cyclic variation of Doppler power from whole blood under pulsatile flow
Tickner Precision microbubbles for right side intracardiac pressure and flow measurements
Hindle et al. A perfusion phantom for the evaluation of ultrasound contrast agents
Fan et al. Comparison of various agents in contrast enhancement of color Doppler flow images: an in vitro study
Hills et al. Evaluation of ultrasonic bubble detectors in vitro using calibrated microbubbles at selected velocities
Perkins et al. A simple simulation for the visualisation of CSF flow in infants with hydrocephalus
Lam et al. Noninvasive cerebrospinal fluid shunt flow measurement by Doppler ultrasound using ultrasonically excited bubbles: a feasibility study
Moehring et al. Exploration of the embolus to blood power ratio model (EBR) for characterizing microemboli detected in the middle cerebral artery
DeMaria et al. Determination of cardiac output by two-dimensional contrast echocardiography
James et al. Impact of Activation Threshold Selection and Data Averaging to Improve Pressure Estimation using Ultrasound Imaging and Phase-Change Contrast Agents
Meltzer et al. The source of echocardiographic contrast
BALZER REINHARD SCHLIEF, ROLF SCHÜRMANN, THOMAS BALZER, MICHAEL ZOMACK & HANS-PETER NIENDORF

Legal Events

Date Code Title Description
MKEX Expiry